



CVE-2022-45611

[MITRE](#)[NVD](#)[CVE.ORG](#)[JSON API](#)[Print: PDF](#)

Summary

CVE	CVE-2022-45611
State	PUBLIC
Assigner	cve@mitre.org
Source Priority	CVE Program / NVD first with legacy fallback
Published	2023-08-22 19:16:00 UTC
Updated	2024-01-10 03:15:00 UTC
Description	An issue was discovered in Fresenius Kabi PharmaHelp 5.1.759.0 allows attackers to gain escalated privileges via via capt

Risk And Classification

Problem Types: CWE-522

NVD Known Affected Configurations (CPE 2.3)

Type	Vendor	Product	Version	Update	Edition	Language
Hardware	Fresenius-kabi	Pharmahelp	-	All	All	All
Operating System	Fresenius-kabi	Pharmahelp Firmware	5.1.759.0	All	All	All

References

Reference	Source	Link	Tags
www.fresenius.com/sites/default/files/2023-11/Fresenius%20-%20CVE-2022-45611.pdf		www.fresenius.com	
www.fresenius.com/sites/default/files/2023-12/Fresenius%20-%20CVE-2022-45611.pdf		www.fresenius.com	
PharmaHelp Compounder - Fresenius Kabi Austria	MISC	www.fresenius-kabi.com	
CVE Program record	CVE.ORG	www.cve.org	canonical
NVD vulnerability detail	NVD	nvd.nist.gov	canonical, &

No vendor comments have been submitted for this CVE.

There are currently no legacy QID mappings associated with this CVE.

this information or its use. Any use of this information is at the user's risk. It is the responsibility of user to evaluate the accuracy, completeness or usefulness of any information, opinion, advice or other content. EACH USER WILL BE SOLELY RESPONSIBLE FOR ANY consequences of his or her direct or indirect use of this web site. ALL WARRANTIES OF ANY KIND ARE EXPRESSLY DISCLAIMED. This site will NOT BE LIABLE FOR ANY DIRECT, INDIRECT or any other kind of loss.

CVE, CWE, and OVAL are registered trademarks of [The MITRE Corporation](#) and the authoritative source of CVE content is [MITRE's CVE web site](#). This site includes MITRE data granted under the following [license](#).

Free CVE JSON API cve.report/api

CVE.report and Source URL Uptime Status status.cve.report